NuProbe is a company developing technologies in genomics for disease detection. It develops a PCR-based (polymerase chain reaction) enrichment method called blocker displacement amplification for selective amplification of low abundant sequence variants in a background of wildtype DNA.
|HQ||Cambridge, MA, US||Map|
|Employees (est.) (Mar 2021)||37||(+13%)|
NuProbe total Funding
NuProbe latest funding size
Time since last funding
|2 months ago|
|WuXi AppTec, Yonghua Capital, Sequoia Capital China, BioTrack Capital, Serica Partners, Taifu Capital, Panlin Capital, Juming Capital, Tuobang Capital, Ruomu Capital|
NuProbe has 31 Twitter Followers. The number of followers has increased 6.9% month over month and increased 14.5% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was NuProbe founded?
NuProbe was founded in 2016.
Who are NuProbe key executives?
NuProbe's key executives are Yingshuang Chai, Nicolas Garreau de Loubresse and Yundi Chen.
How many employees does NuProbe have?
NuProbe has 37 employees.
Who are NuProbe competitors?
Competitors of NuProbe include Serimmune, PathoFinder and Gravity Diagnostics.
Where is NuProbe headquarters?
NuProbe headquarters is located at 85 Bolton St, Cambridge.
Where are NuProbe offices?
NuProbe has offices in Cambridge and Houston.
How many offices does NuProbe have?
NuProbe has 4 offices.
Receive alerts for 300+ data fields across thousands of companies